203 related articles for article (PubMed ID: 21703200)
1. The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.
Mahady SE; Webster AC; Walker S; Sanyal A; George J
J Hepatol; 2011 Dec; 55(6):1383-90. PubMed ID: 21703200
[TBL] [Abstract][Full Text] [Related]
2. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
Said A; Akhter A
Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
Boettcher E; Csako G; Pucino F; Wesley R; Loomba R
Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
[TBL] [Abstract][Full Text] [Related]
4. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
Musso G; Cassader M; Paschetta E; Gambino R
JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.
Ratziu V; Giral P; Jacqueminet S; Charlotte F; Hartemann-Heurtier A; Serfaty L; Podevin P; Lacorte JM; Bernhardt C; Bruckert E; Grimaldi A; Poynard T;
Gastroenterology; 2008 Jul; 135(1):100-10. PubMed ID: 18503774
[TBL] [Abstract][Full Text] [Related]
7. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease.
Musso G; Gambino R; Cassader M; Pagano G
Hepatology; 2010 Jul; 52(1):79-104. PubMed ID: 20578268
[TBL] [Abstract][Full Text] [Related]
9. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
[TBL] [Abstract][Full Text] [Related]
10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis.
Rakoski MO; Singal AG; Rogers MA; Conjeevaram H
Aliment Pharmacol Ther; 2010 Nov; 32(10):1211-21. PubMed ID: 20955440
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials.
He L; Liu X; Wang L; Yang Z
Medicine (Baltimore); 2016 Oct; 95(42):e4947. PubMed ID: 27759627
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.
Singh S; Khera R; Allen AM; Murad MH; Loomba R
Hepatology; 2015 Nov; 62(5):1417-32. PubMed ID: 26189925
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Ratziu V; Charlotte F; Bernhardt C; Giral P; Halbron M; Lenaour G; Hartmann-Heurtier A; Bruckert E; Poynard T;
Hepatology; 2010 Feb; 51(2):445-53. PubMed ID: 19877169
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
Sanyal AJ; Mofrad PS; Contos MJ; Sargeant C; Luketic VA; Sterling RK; Stravitz RT; Shiffman ML; Clore J; Mills AS
Clin Gastroenterol Hepatol; 2004 Dec; 2(12):1107-15. PubMed ID: 15625656
[TBL] [Abstract][Full Text] [Related]
17. The therapeutic landscape of non-alcoholic steatohepatitis.
Perazzo H; Dufour JF
Liver Int; 2017 May; 37(5):634-647. PubMed ID: 27727520
[TBL] [Abstract][Full Text] [Related]
18. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.
Chalasani NP; Sanyal AJ; Kowdley KV; Robuck PR; Hoofnagle J; Kleiner DE; Unalp A; Tonascia J;
Contemp Clin Trials; 2009 Jan; 30(1):88-96. PubMed ID: 18804555
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]